Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07168915
PHASE1

A Study of V118E in Healthy Participants (V118E-003)

Sponsor: Merck Sharp & Dohme LLC

View on ClinicalTrials.gov

Summary

Researchers are looking for new vaccines to prevent illnesses caused by a type of bacteria called Streptococcus pneumoniae. There are many different types of Streptococcus pneumoniae bacteria, called serotypes. Vaccines contain small parts of certain serotypes. These parts will not cause an infection but help the body create antibodies (proteins) to fight the bacteria. PREVNAR 20™ is a vaccine given to help to prevent disease from Streptococcus pneumoniae bacteria. Researchers designed a new vaccine, V118E, to help prevent disease from Streptococcus pneumoniae bacteria. The goal of this study is to learn how safe V118 formulation E is in Healthy Adults and how well people tolerate it.

Official title: A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V118 Formulation E in Healthy Adults

Key Details

Gender

All

Age Range

18 Years - 49 Years

Study Type

INTERVENTIONAL

Enrollment

126

Start Date

2025-10-08

Completion Date

2027-11-12

Last Updated

2026-02-27

Healthy Volunteers

Yes

Conditions

Interventions

BIOLOGICAL

V118E

IM administration

BIOLOGICAL

PREVNAR 20™

IM administration

BIOLOGICAL

Saline

IM administration

Locations (4)

Velocity Clinical Research, Hallandale Beach ( Site 0003)

Hallandale, Florida, United States

QPS-MRA, LLC-Early Phase ( Site 0002)

South Miami, Florida, United States

Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0004)

Springfield, Missouri, United States

University of Texas Medical Branch ( Site 0001)

Galveston, Texas, United States